

## References

---

This is the reference list for the ACE Clinical Guideline "Generalised anxiety disorder – easing burden and enabling remission".

1. Abdin E, Chong SA, Vaingankar JA, et al. Impact of mental disorders and chronic physical conditions on quality-adjusted life years in Singapore. *Sci Rep*. 2020;10(1):2695.
2. Ten Have M, Tuithof M, van Dorsselaer S, et al. Duration of anxiety disorder and its associated risk indicators: Results of a longitudinal study of the general population. 2020.
3. Hovenkamp-Hermelink JHM, Jeronimus BF, Myroniuk S, et al. Predictors of persistence of anxiety disorders across the lifespan: a systematic review. *Lancet Psychiatry*. 2021;8(5):428–443.
4. Spitzer RL, Kroenke K, Williams JB, et al. A Brief Measure for Assessing Generalized Anxiety Disorder: The GAD-7. *Arch Intern Med*. 2006;166(10):1092-1097.
5. Khosravi M, Azar G, Izadi R. Principles and elements of patient-centredness in mental health services: a thematic analysis of a systematic review of reviews. *BMJ Open Qual*. 2024;13(3).
6. Zubkoff L, Carpenter-Song E, Shiner B, et al. Clinicians' Perception of Patient Readiness for Treatment: An Emerging Theme in Implementation Science? *Adm Policy Ment Health*. 2016;43(2):250-258.
7. Franklin C, Ding X, Kim J, et al. Solution-Focused Brief Therapy in Community-Based Services: A Meta-Analysis of Randomized Controlled Studies. *Research on Social Work Practice*. 2023;34(3):265-276.
8. Hendriks GJ, Janssen N, Robertson L, et al. Cognitive behavioural therapy and third-wave approaches for anxiety and related disorders in older people. *Cochrane Database Syst Rev*. 2024;7(7):Cd007674.
9. Tay KW, Subramaniam P, Oei TP. Cognitive behavioural therapy can be effective in treating anxiety and depression in persons with dementia: a systematic review. *Psychogeriatrics*. 2019;19(3):264-275.
10. Rossiter R, Holmes S. Access all areas: creative adaptations for CBT with people with cognitive impairments – illustrations and issues. *The Cognitive Behaviour Therapist*. 2013;6:e9.
11. Ganesh Kudva K, Abdin E, Vaingankar JA, et al. The Relationship between Suicidality and Socio-Demographic Variables, Physical Disorders, and Psychiatric Disorders: Results from the Singapore Mental Health Study 2016. *Int J Environ Res Public Health*. 2021;18(8):4365.
12. Deering K, Pawson C, Summers N, et al. Patient perspectives of helpful risk management practices within mental health services. A mixed studies systematic review of primary research. *J Psychiatr Ment Health Nurs*. 2019;26(5-6):185-197.
13. Singh B, Olds T, Curtis R, et al. Effectiveness of physical activity interventions for improving depression, anxiety and distress: an overview of systematic reviews. *Br J Sports Med*. 2023;57(18):1203-1209.
14. Martínez-Calderon J, Casuso-Holgado MJ, Muñoz-Fernandez MJ, et al. Yoga-based interventions may reduce anxiety symptoms in anxiety disorders and depression symptoms in depressive disorders: a systematic review with meta-analysis and meta-regression. *Br J Sports Med*. 2023;57(22):1442-1449.
15. Yin J, Yue C, Song Z, et al. The comparative effects of Tai chi versus non-mindful exercise on measures of anxiety, depression and general mental health: A systematic review and meta-analysis. *J Affect Disord*. 2023;337:202-214.
16. Chang PS, Knobf T, Oh B, et al. Physical and Psychological Health Outcomes of Qigong Exercise in Older Adults: A Systematic Review and Meta-Analysis. *Am J Chin Med*. 2019;47(2):301-322.

17. Dolan N, Simmonds-Buckley M, Kellett S, et al. Effectiveness of stress control large group psychoeducation for anxiety and depression: Systematic review and meta-analysis. *Br J Clin Psychol*. 2021;60(3):375-399.
18. Klevebrant L, Frick A. Effects of caffeine on anxiety and panic attacks in patients with panic disorder: A systematic review and meta-analysis. *Gen Hosp Psychiatry*. 2022;74:22-31.
19. Papola D, Miguel C, Mazzaglia M, et al. Psychotherapies for Generalized Anxiety Disorder in Adults: A Systematic Review and Network Meta-Analysis of Randomized Clinical Trials. *JAMA Psychiatry*. 2024;81(3):250-259.
20. Cuijpers P, Miguel C, Ciharova M, et al. Absolute and relative outcomes of psychotherapies for eight mental disorders: a systematic review and meta-analysis. *World Psychiatry*. 2024;23(2):267-275.
21. Parker EL, Banfield M, Fassnacht DB, et al. Contemporary treatment of anxiety in primary care: a systematic review and meta-analysis of outcomes in countries with universal healthcare. *BMC Fam Pract*. 2021;22(1):92.
22. Cuijpers P, Miguel C, Ciharova M, et al. Transdiagnostic treatment of depression and anxiety: a meta-analysis. *Psychol Med*. 2023:1-12.
23. Slee A, Nazareth I, Bondaronek P, et al. Pharmacological treatments for generalised anxiety disorder: a systematic review and network meta-analysis. *Lancet*. 2019;393(10173):768-777.
24. Kopcalic K, Arcaro J, Pinto A, et al. Antidepressants versus placebo for generalised anxiety disorder (GAD). *Cochrane Database Syst Rev*. 2025;1(1):Cd012942.
25. Mendez EM, Mills JA, Suresh V, et al. Trajectory and magnitude of response in adults with anxiety disorders: a Bayesian hierarchical modeling meta-analysis of selective serotonin reuptake inhibitors, serotonin norepinephrine reuptake inhibitors, and benzodiazepines. *CNS Spectr*. 2024;29(3):187-196.
26. Gosmann NP, Costa MA, Jaeger MB, et al. Selective serotonin reuptake inhibitors, and serotonin and norepinephrine reuptake inhibitors for anxiety, obsessive-compulsive, and stress disorders: A 3-level network meta-analysis. *PLoS Med*. 2021;18(6):e1003664.
27. Stone M, Laughren T, Jones ML, et al. Risk of suicidality in clinical trials of antidepressants in adults: analysis of proprietary data submitted to US Food and Drug Administration. *Bmj*. 2009;339:b2880.
28. Guaiana G, Barbui C, Cipriani A. Hydroxyzine for generalised anxiety disorder (Review). *Cochrane Database Syst Rev*. 2010(12):CD006815.
29. Sarris J, Ravindran A, Yatham LN, et al. Clinician guidelines for the treatment of psychiatric disorders with nutraceuticals and phytoceuticals: The World Federation of Societies of Biological Psychiatry (WFSBP) and Canadian Network for Mood and Anxiety Treatments (CANMAT) Taskforce. *World J Biol Psychiatry*. 2022;23(6):424-455.
30. Strauss B, Gawlytta R, Schleu A, et al. Negative effects of psychotherapy: estimating the prevalence in a random national sample. 2021.
31. Xie ZJ, Han N, Law S, et al. The efficacy of group cognitive-behavioural therapy plus duloxetine for generalised anxiety disorder versus duloxetine alone. *Acta neuropsychiatrica*. 2019;31(6):316-324.
32. Crits-Christoph P, Newman MG, Rickels K, et al. Combined Medication and Cognitive Therapy for Generalized Anxiety Disorder. *J Anxiety Disord*. 2011;25(8):1087-1094.
33. Tan XW, Chong SA, Abidin E, et al. Comorbidities within mental illnesses in a multiethnic urban population. *Asian J Psychiatr*. 2020(51):102018.
34. Ionescu DF, Niciu MJ, Richards EM, et al. Pharmacologic treatment of dimensional anxious depression: a review. *Prim Care Companion CNS Disord*. 2014;16(3).
35. Williams T, McCaul M, Schwarzer G, et al. Pharmacological treatments for social anxiety disorder in adults: a systematic review and network meta-analysis. *Acta Neuropsychiatr*. 2020;32(4):169-176.

36. Guaiana G, Meader N, Barbui C, et al. Pharmacological treatments in panic disorder in adults: a network meta-analysis. *Cochrane Database Syst Rev*. 2023;11(11):Cd012729.
37. Schaeuffele C, Meine LE, Schulz A, et al. A systematic review and meta-analysis of transdiagnostic cognitive behavioural therapies for emotional disorders. *Nat Hum Behav*. 2024;8(3):493-509.
38. Cuijpers P, Sijbrandij M, Koole SL, et al. Adding psychotherapy to antidepressant medication in depression and anxiety disorders: a meta-analysis. *World Psychiatry*. 2014;13(1):56-67.
39. Cuijpers P, Noma H, Karyotaki E, et al. A network meta-analysis of the effects of psychotherapies, pharmacotherapies and their combination in the treatment of adult depression. *World Psychiatry*. 2020;19(1):92-107.
40. Mayo-Wilson E, Dias S, Mavranezouli I, et al. Psychological and pharmacological interventions for social anxiety disorder in adults: a systematic review and network meta-analysis. *Lancet Psychiatry*. 2014;1(5):368-376.
41. Bauer-Staeb C, Kounali DZ, Welton NJ, et al. Effective dose 50 method as the minimal clinically important difference: Evidence from depression trials. *J Clin Epidemiol*. 2021;137:200-208.
42. Kounali D, Button KS, Lewis G, et al. How much change is enough? Evidence from a longitudinal study on depression in UK primary care. *Psychological Medicine*. 2022;52(10):1875-1882.
43. Roy-Byrne P. Treatment-refractory anxiety; definition, risk factors, and treatment challenges. *Dialogues Clin Neurosci*. 2015;17(2):191-206.
44. Campbell-Sills L, Roy-Byrne PP, Craske MG, et al. Improving outcomes for patients with medication-resistant anxiety: effects of collaborative care with cognitive behavioral therapy. *Depress Anxiety*. 2016;33(12):1099-1106.
45. Giommi F, Castagner V, Zaccaro A, et al. Mindfulness-based cognitive therapy vs. psycho-education for patients with anxiety disorders who did not achieve remission following adequate pharmacological treatment. *Mindfulness*. 2021;12(8):2059-2075.
46. Batelaan NM, Bosman RC, Muntingh A, et al. Risk of relapse after antidepressant discontinuation in anxiety disorders, obsessive-compulsive disorder, and post-traumatic stress disorder: systematic review and meta-analysis of relapse prevention trials. *Bmj*. 2017;358:j3927.
47. Zhou D, Zhou X, Lin Q, et al. Nonpharmacological interventions for relapse prevention in unipolar depression: A network meta-analysis. *J Affect Disord*. 2021;282:1255-1262.
48. Horowitz M, Taylor D. The Maudsley Deprescribing Guidelines: Antidepressants, Benzodiazepines, Gabapentinoids and Z- drugs. Hoboken, NJ: Wiley; 2024.
49. Stimpfl JN, Mills JA, Strawn JR. Pharmacologic predictors of benzodiazepine response trajectory in anxiety disorders: a Bayesian hierarchical modeling meta-analysis. *CNS Spectr*. 2023;28(1):53-60.
50. US Federal Drug Administration. FDA Drug Safety Communication: FDA requiring Boxed Warning updated to improve safe use of benzodiazepine drug class 2020 Available from: <https://www.fda.gov/drugs/drug-safety-and-availability/fda-requiring-boxed-warning-updated-improve-safe-use-benzodiazepine-drug-class>. [Accessed: 30 June 2024]
51. Baldwin DS, Aitchison K, Bateson A, et al. Benzodiazepines: risks and benefits. A reconsideration. *J Psychopharmacol*. 2013;27(11):967-971.
52. Lam RW, Kennedy SH, Adams C, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2023 Update on Clinical Guidelines for Management of Major Depressive Disorder in Adults: Réseau canadien pour les traitements de l'humeur et de l'anxiété (CANMAT) 2023 : Mise à jour des lignes directrices cliniques pour la prise en charge du trouble dépressif majeur chez les adultes. *Can J Psychiatry*. 2024;69(9):641-687.
53. Taylor D, Barnes TRE, Young AH. The Maudsley Prescribing Guidelines in Psychiatry (14th edition). Hoboken, NJ: Wiley; 2021.

54. Specialist Pharmacy Service. Choosing an antidepressant for people with coronary heart disease. 2023. Available from: [sps.nhs.uk/articles/choosing-an-antidepressant-for-people-with-coronary-heart-disease/](https://sps.nhs.uk/articles/choosing-an-antidepressant-for-people-with-coronary-heart-disease/) [Accessed: 1 October 2024]
55. Vandael E, Vandenberg B, Vandenberghe J, et al. Risk factors for QTc-prolongation: systematic review of the evidence. *Int J Clin Pharm*. 2017;39(1):16-25.
56. Funk KA, Bostwick JR. A comparison of the risk of QT prolongation among SSRIs. *Ann Pharmacother*. 2013;47(10):1330-1341.
57. Mikkelsen N, Damkier P, Pedersen SA. Serotonin syndrome-A focused review. *Basic Clin Pharmacol Toxicol*. 2023;133(2):124-129.
58. Keks N, Hope J, Keogh S. Switching and stopping antidepressants. *Aust Prescr*. 2016;39(3):76-83.
59. Specialist Pharmacy Service. SSRIs to other antidepressants: switching in adults. 2023 Available from: <https://www.sps.nhs.uk/articles/ssris-to-other-antidepressants-switching-in-adults/> [Accessed: 1 October 2024]
60. Ogle NR, Akkerman SR. Guidance for the Discontinuation or Switching of Antidepressant Therapies in Adults. *Journal of Pharmacy Practice*. 2013;26(4):389-396.
61. Hirsch M, Birnbaum RJ. Switching antidepressant medications in adults. UpToDate; 2023. Available from: [Switching antidepressant medications in adults - UpToDate](#) [Accessed: 1 December 2024]
62. Specialist Pharmacy Service. SNRIs to other antidepressants: switching in adults 2023 Available from: <https://www.sps.nhs.uk/articles/snr-is-to-other-antidepressants-switching-in-adults/> [Accessed: 1 October 2024]
63. Chen H, Chua TE, Lee TMY, et al. Consensus statement on Singapore Perinatal Mental Health Guidelines on Depression and Anxiety. *Ann Acad Med Singap*. 2023;52(9):467-475.
64. Misri S, Abizadeh J, Sanders S, et al. Perinatal Generalized Anxiety Disorder: Assessment and Treatment. *J Womens Health (Larchmt)*. 2015;24(9):762-770.
65. Callanan F, Tuohy T, Bright AM, et al. The effectiveness of psychological interventions for pregnant women with anxiety in the antenatal period: A systematic review. *Midwifery*. 2022;104:103169.
66. Zimmermann M, Julce C, Sarkar P, et al. Can psychological interventions prevent or reduce risk for perinatal anxiety disorders? A systematic review and meta-analysis. *Gen Hosp Psychiatry*. 2023;84:203-214.
67. Pettman D, O'Mahen H, Blomberg O, et al. Effectiveness of cognitive behavioural therapy-based interventions for maternal perinatal depression: a systematic review and meta-analysis. *BMC Psychiatry*. 2023;23(1):208.
68. Viswanathan M, Middleton JC, Stuebe A, et al. Maternal, Fetal, and Child Outcomes of Mental Health Treatments in Women: A Systematic Review of Perinatal Pharmacologic Interventions. Agency for Healthcare Research and Quality; 2021.
69. Couch E, Mai HJ, Kanaan G, et al. Nonpharmacologic Treatments for Maternal Mental Health Conditions. AHRQ Comparative Effectiveness Reviews. 2024.
70. Milgrom J, Gemmill AW, Bilszta JL, et al. Antenatal risk factors for postnatal depression: a large prospective study. *J Affect Disord*. 2008;108(1-2):147-157.
71. Chen LM, Pokhvisneva I, Lahti-Pulkkinen M, et al. Independent Prediction of Child Psychiatric Symptoms by Maternal Mental Health and Child Polygenic Risk Scores. *J Am Acad Child Adolesc Psychiatry*. 2024;63(6):640-651.
72. Martini J, Knappe S, Beesdo-Baum K, et al. Anxiety disorders before birth and self-perceived distress during pregnancy: Associations with maternal depression and obstetric, neonatal and early childhood outcomes. *Early Human Development*. 2010;86(5):305-310.
73. Fabiano N, Wong S, Gupta A, et al. Safety of psychotropic medications in pregnancy: an umbrella review. *Mol Psychiatry*. 2024.

74. Kautzky A, Slamanig R, Unger A, et al. Neonatal outcome and adaption after in utero exposure to antidepressants: A systematic review and meta-analysis. *Acta Psychiatr Scand*. 2022;145(1):6-28.
75. Fallon V, Silverio SA, Halford JCG, et al. Postpartum-specific anxiety and maternal bonding: Further evidence to support the use of childbearing specific mood tools. *J Reprod Infant Psychol*. 2021;39(2):114-124.
76. Vigod SN, Frey BN, Clark CT, et al. Canadian Network for Mood and Anxiety Treatments 2024 Clinical Practice Guideline for the Management of Perinatal Mood, Anxiety, and Related Disorders: Guide de pratique 2024 du Canadian Network for Mood and Anxiety Treatments pour le traitement des troubles de l'humeur, des troubles anxieux et des troubles connexes périnataux. *Can J Psychiatry*. 2025:7067437241303031.
77. National Institute of Child Health and Human Development. Drugs and Lactation Database (LactMed®) – Sertraline. 2025. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK501191/> [Accessed: 13 Feb 2025]
78. Creswell C, Waite P, Cooper PJ. Assessment and management of anxiety disorders in children and adolescents. *Arch Dis Child*. 2014;99(7):674-678.
79. Walter HJ, Bukstein OG, Abright AR, et al. Clinical Practice Guideline for the Assessment and Treatment of Children and Adolescents With Anxiety Disorders. *J Am Acad Child Adolesc Psychiatry*. 2020;59(10):1107-1124.
80. Klein B, Rajendram R, Hrycko S, et al. Anxiety in children and youth: Part 1—Diagnosis. *Paediatrics & Child Health*. 2023;28(1):45-51.
81. Koura R., Davis C. Using the HEADSS assessment to screen for adolescent mental health concerns in the community. *Singapore Family Physician*. 2023;49(8):14-19.
82. Doukrou M, Segal TY. Fifteen-minute consultation: Communicating with young people—how to use HEEADSSS, a psychosocial interview for adolescents. *Arch Dis Child Educ Pract Ed*. 2018;103(1):15-19.
83. Wuthrich VM, Zagic D, Dickson SJ, et al. Effectiveness of Psychotherapy for Internalising Symptoms in Children and Adolescents When Delivered in Routine Settings: A Systematic Review and Meta-analysis. *Clin Child Fam Psychol Rev*. 2023;26(3):824-848.
84. Schwartz C, Barican JL, Yung D, et al. Six decades of preventing and treating childhood anxiety disorders: a systematic review and meta-analysis to inform policy and practice. *Evid Based Ment Health*. 2019;22(3):103-110.
85. Zbukvic I, McKay S, Cooke S, et al. Evidence for targeted and universal secondary school-based programs for anxiety and depression: An overview of systematic reviews. *Adolescent Research Review*. 2024;9(1):53-73.
86. Goger P, Weersing VR. Family based treatment of anxiety disorders: A review of the literature (2010–2019). *Journal of Marital and Family Therapy*. 2022;48(1):107-128.
87. Jewell C, Wittkowski A, Pratt D. The impact of parent-only interventions on child anxiety: A systematic review and meta-analysis. *J Affect Disord*. 2022;309:324-349.
88. Wang Z, Whiteside SPH, Sim L, et al. Comparative Effectiveness and Safety of Cognitive Behavioral Therapy and Pharmacotherapy for Childhood Anxiety Disorders: A Systematic Review and Meta-analysis. *JAMA Pediatr*. 2017;171(11):1049-1056.
89. Walkup JT, Albano AM, Piacentini J, et al. Cognitive Behavioral Therapy, Sertraline, or a Combination in Childhood Anxiety. *N Engl J Med*. 2008;359(26):2753-2766.